Phase 1 Malignancies Clinical Trials
110 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–20 of 110 trials
Recruiting
Phase 1
Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies
Leukemia, Lymphocytic, AcuteBlood CancerMyeloid Leukemia, Acute+8 more
National Cancer Institute (NCI)86 enrolled1 locationNCT06904066
Recruiting
Phase 1
A Drug-drug Interaction Study to Evaluate the Effects of Pelabresib on the Pharmacokinetics of Repaglinide, Midazolam, and Combined Oral Contraceptive in Patients With Advanced Malignancies
Advanced Malignancies
Novartis Pharmaceuticals24 enrolled3 locationsNCT07340190
Recruiting
Phase 1
Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation
Myelodysplastic SyndromesRelapsed or Refractory Acute Myeloid Leukemia (AML)Untreated AML+1 more
Institut de Recherches Internationales Servier291 enrolled30 locationsNCT02074839
Recruiting
Phase 1Phase 2
Phase I/II Study of Engineered T Cell Receptor-Modified NK Cells Targeting PRAME in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Myeloid Malignancies
Myeloid MalignanciesLymphodepleting Chemotherapy
M.D. Anderson Cancer Center44 enrolled1 locationNCT06383572
Recruiting
Phase 1
Radiologic Pathologic Correlation of Imaging to Distinguish True Progression From Pseudoprogression in Brain Malignancies
Brain MalignanciesPseudoprogression
M.D. Anderson Cancer Center25 enrolled1 locationNCT06199479
Recruiting
Phase 1
Dose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell Malignancies
Diffuse Large B-Cell Lymphoma (DLBCL)Follicular Lymphoma ( FL)Mantle Cell Lymphoma (MCL)+4 more
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.85 enrolled9 locationsNCT06980116
Recruiting
Phase 1Phase 2
Study of PM54 in Combination With Immunotherapy in Adult Participants With Advanced Malignancies
Advanced Malignancies
PharmaMar119 enrolled6 locationsNCT07644039
Recruiting
Phase 1Phase 2
Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies ...
Hematologic MalignanciesHIV
National Cancer Institute (NCI)265 enrolled1 locationNCT05470491
Recruiting
Phase 1
Pharmacokinetics and Safety Study of Pelabresib in Patients With Advanced Malignancies and Hepatic Impairment
Advanced Malignancies and Hepatic Impairment
Novartis Pharmaceuticals24 enrolled5 locationsNCT07422610
Recruiting
Phase 1Phase 2
Ph. I/II Sodium Thiosulfate for OtoProtection During Cisplatin (STOP-CIS)
Head and Neck CancerThoracic CancerTesticular Cancer+1 more
University of Arizona25 enrolled1 locationNCT07407582
Recruiting
Phase 1
Phase I Trial Integrating HLA-Haploidentical Anti-CD19 CAR-T Cells With Post-Transplantation Cyclophosphamide-Based HLA-Haploidentical Hematopoietic Cell Transplantation
Hematologic NeoplasmsHematologic Malignancies
National Cancer Institute (NCI)155 enrolled1 locationNCT07162038
Recruiting
Phase 1
Pomalidomide and Nivolumab in People With Virus-Associated Malignancies With or Without HIV
Kaposi SarcomaViral Associated MalignanciesEBV/KSHV-associated Lymphomas
National Cancer Institute (NCI)58 enrolled1 locationNCT04902443
Recruiting
Phase 1
A Study of BL-M24D1 in Patients With Relapsed or Refractory Multiple Myeloma and Other Hematologic Malignancies
Multiple MyelomaHematologic Malignancies
Sichuan Baili Pharmaceutical Co., Ltd.33 enrolled1 locationNCT07255898
Recruiting
Phase 1
Imatinib to Increase RUNX1 Activity in Participants With Germline RUNX1 Deficiency
Inherited Bone Marrow Failure SyndromeFamilial Platelet Disorder With Predisposition to Myeloid Malignancies
National Cancer Institute (NCI)75 enrolled1 locationNCT06090669
Recruiting
Phase 1Phase 2
Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
Advanced Solid Malignancies
AstraZeneca695 enrolled32 locationsNCT05417594
Recruiting
Phase 1
An Open-Label Study to Evaluate PF-07994525 in Participants With Advanced Cancers
Advanced CancerAdvanced Malignancies
Pfizer120 enrolled4 locationsNCT07426757
Recruiting
Phase 1
IASO208 Injection in the Treatment of Relapsed/Refractory B-cell Malignancies
Relapsed/Refractory B-cell Malignancies
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology12 enrolled1 locationNCT07309900
Recruiting
Phase 1
Study to Assess Safety, Tolerability and Activity of DSB2455 in Participants With Advanced Malignancies
Advanced Malignancies With Homologous Recombination Deficiency (HRD) (Breast, Ovarian, mCRPC, Brain Metastases)
Duke Street Bio Ltd180 enrolled15 locationsNCT06458712
Recruiting
Phase 1Phase 2
A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies
Non-small Cell Lung Cancer (NSCLC)Pancreatic Ductal Adenocarcinoma (PDAC)Advanced Solid Malignancies+1 more
Bristol-Myers Squibb252 enrolled8 locationsNCT07223047
Recruiting
Phase 1
Controlled Cold Exposure Combined With PD-1/PD-L1 Immunotherapy in Solid Tumors (NIVALIS)
Solid TumorsImmunotherapyCold Exposure+1 more
West China Hospital24 enrolled1 locationNCT07538479